{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:11:05Z","timestamp":1783588265992,"version":"3.55.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.leukres.2026.108197","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:49:50Z","timestamp":1772207390000},"page":"108197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Measurable residual disease detection in acute leukemia: Technological advances and clinical translation"],"prefix":"10.1016","volume":"163","author":[{"given":"Meixin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.leukres.2026.108197_bib1","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2026.108197_bib2","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.leukres.2026.108197_bib3","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2026.108197_bib4","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108197_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol."},{"issue":"16","key":"10.1016\/j.leukres.2026.108197_bib6","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2026.108197_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2026.108197_bib8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"D\u00f6hner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108197_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2026.108197_bib10","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","article-title":"Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study","volume":"33","author":"Br\u00fcggemann","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2026.108197_bib11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"16","key":"10.1016\/j.leukres.2026.108197_bib12","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2018-12-852376","article-title":"Taking a \"BiTE out of ALL\": blinatumomab approval for MRD-positive ALL","volume":"133","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2026.108197_bib13","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3390\/jcm9061714","article-title":"Measurable residual disease in acute myeloid leukemia using flow cytometry: a review of where we are and where we are going","volume":"9","author":"Dix","year":"2020","journal-title":"J. Clin. Med"},{"issue":"5","key":"10.1016\/j.leukres.2026.108197_bib14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ajcp\/aqae187","article-title":"Flow cytometry evaluation of acute myeloid leukemia minimal residual disease based on an understanding of the normal maturation patterns in the blast compartments","volume":"163","author":"Roshal","year":"2025","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2026.108197_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party","volume":"6","author":"Tettero","year":"2022","journal-title":"HemaSphere"},{"issue":"12","key":"10.1016\/j.leukres.2026.108197_bib16","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","article-title":"The present and future of measurable residual disease testing in acute myeloid leukemia","volume":"107","author":"Blachly","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2026.108197_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cyto.b.22143","article-title":"Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: a EuroFlow study","volume":"106","author":"Verbeek","year":"2024","journal-title":"Cytom. B Clin. Cytom."},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib18","doi-asserted-by":"crossref","DOI":"10.1515\/med-2023-0745","article-title":"Twenty-four-color full spectrum flow cytometry panel for minimal residual disease detection in acute myeloid leukemia","volume":"18","author":"Chen","year":"2023","journal-title":"Open Med."},{"issue":"3","key":"10.1016\/j.leukres.2026.108197_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/cyto.a.24811","article-title":"A 19-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia","volume":"105","author":"Fokken","year":"2024","journal-title":"Cytom. A"},{"issue":"9","key":"10.1016\/j.leukres.2026.108197_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cyto.a.24958","article-title":"Development of a 29-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease and leukemic stem cells in acute myeloid leukemia","volume":"107","author":"Zhang","year":"2025","journal-title":"Cytom. A"},{"issue":"3","key":"10.1016\/j.leukres.2026.108197_bib21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cncr.30361","article-title":"Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia","volume":"123","author":"Ravandi","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.leukres.2026.108197_bib22","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.3390\/ijms25094881","article-title":"The evolving landscape of flowcytometric MRD monitoring in B-cell precursor ALL","volume":"25","author":"Verbeek","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.leukres.2026.108197_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s43856-024-00700-x","article-title":"Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models","volume":"4","author":"Mocking","year":"2024","journal-title":"Commun. Med"},{"issue":"4","key":"10.1016\/j.leukres.2026.108197_bib24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bjh.18833","article-title":"From gating to computational flow cytometry: exploiting artificial intelligence for MRD diagnostics","volume":"202","author":"Riva","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108197_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70138","article-title":"Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemia","volume":"9","author":"Mocking","year":"2025","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.leukres.2026.108197_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.semdp.2023.02.004","article-title":"Artificial intelligence in clinical multiparameter flow cytometry and mass cytometry: key tools and progress","volume":"40","author":"Fuda","year":"2023","journal-title":"Semin Diagn. Pathol."},{"issue":"9","key":"10.1016\/j.leukres.2026.108197_bib27","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cyto.a.23852","article-title":"Automated flow cytometric MRD assessment in childhood acute B-lymphoblastic leukemia using supervised machine learning","volume":"95","author":"Reiter","year":"2019","journal-title":"Cytom. A"},{"issue":"9","key":"10.1016\/j.leukres.2026.108197_bib28","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/ijms20092249","article-title":"Digital PCR in myeloid malignancies: ready to replace quantitative PCR?","volume":"20","author":"Cilloni","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.leukres.2026.108197_bib29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/2643-3230.BCD-23-0144","article-title":"Criteria for diagnosis and molecular monitoring of NPM1-mutated AML","volume":"5","author":"Falini","year":"2024","journal-title":"Blood Cancer Discov."},{"issue":"6","key":"10.1016\/j.leukres.2026.108197_bib31","first-page":"97","article-title":"Core binding factor acute myelogenous leukemia-2021 treatment algorithm","volume":"11","author":"Dillon","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108197_bib32","doi-asserted-by":"crossref","unstructured":"Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML. Blood Adv. 2025;9(11):2577-2587.","DOI":"10.1182\/bloodadvances.2024014490"},{"issue":"93","key":"10.1016\/j.leukres.2026.108197_bib33","doi-asserted-by":"crossref","first-page":"36613","DOI":"10.18632\/oncotarget.26400","article-title":"Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia","volume":"9","author":"Patkar","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.leukres.2026.108197_bib34","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2018.04.017","article-title":"Deep NPM1 sequencing following allogeneic hematopoietic cell transplantation improves risk assessment in adults with NPM1-mutated AML","volume":"24","author":"Zhou","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"5","key":"10.1016\/j.leukres.2026.108197_bib35","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","article-title":"Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)","volume":"35","author":"Patkar","year":"2021","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.leukres.2026.108197_bib36","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1182\/bloodadvances.2024013758","article-title":"Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin","volume":"8","author":"R\u00fccker","year":"2024","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.leukres.2026.108197_bib37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2026.108197_bib38","first-page":"1061","article-title":"A new view on minimal residual disease quantification in acute lymphoblastic leukemia using droplet digital PCR","volume":"24","author":"Moor","year":"2022","journal-title":"J. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.leukres.2026.108197_bib39","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","article-title":"Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients","volume":"97","author":"Bill","year":"2018","journal-title":"Ann. Hematol."},{"issue":"13","key":"10.1016\/j.leukres.2026.108197_bib40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108197_bib41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fcell.2020.00249","article-title":"Sequencing-based measurable residual disease testing in acute myeloid leukemia","volume":"8","author":"Yoest","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"13","key":"10.1016\/j.leukres.2026.108197_bib42","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.leukres.2026.108197_bib43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.leukres.2026.108197_bib44","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108197_bib45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.2023023699","article-title":"How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL","volume":"144","author":"Muffly","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2026.108197_bib46","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.2023.283520","article-title":"Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia","volume":"109","author":"Dillon","year":"2024","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.leukres.2026.108197_bib47","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","article-title":"Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)","volume":"35","author":"Patkar","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib48","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2024-201701","article-title":"Circulating tumor DNA (ctDNA) enables superior and universal measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) highly predictive of relapse free and overall survival","volume":"144","author":"Gunaratne","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib49","article-title":"Cell-free DNA for detection and monitoring of extramedullary AML relapse","volume":"9","author":"Hupe","year":"2025","journal-title":"HemaSphere"},{"issue":"38","key":"10.1016\/j.leukres.2026.108197_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg0488","article-title":"Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia","volume":"9","author":"Robinson","year":"2023","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.leukres.2026.108197_bib51","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s11427-024-2666-8","article-title":"Single-cell immune landscape of measurable residual disease in acute myeloid leukemia","volume":"67","author":"Mo","year":"2024","journal-title":"Sci. China Life Sci."},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib52","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/hematology.2023000454","article-title":"Understanding differential technologies for detection of MRD and how to incorporate into clinical practice","volume":"2023","author":"Cloos","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.leukres.2026.108197_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-021-01148-5","article-title":"Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia","volume":"14","author":"Aitken","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108197_bib54","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1038\/s41375-022-01692-0","article-title":"Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis","volume":"36","author":"Short","year":"2022","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.leukres.2026.108197_bib55","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/bloodadvances.2022009391","article-title":"Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity","volume":"7","author":"Bazinet","year":"2023","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.leukres.2026.108197_bib56","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2026.108197_bib57","first-page":"4529","article-title":"Impact of measurable residual disease clearance kinetics in acute myeloid leukemia undergoing intensive chemotherapy","volume":"8","author":"Short","year":"2024","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.leukres.2026.108197_bib58","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2026.108197_bib59","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT","volume":"105","author":"Dholaria","year":"2020","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.leukres.2026.108197_bib61","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2026.108197_bib62","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"21","key":"10.1016\/j.leukres.2026.108197_bib63","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood.2024027500","article-title":"Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study","volume":"145","author":"Bassan","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2026.108197_bib64","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.leukres.2026.108197_bib65","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's oncology group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108197_bib66","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","article-title":"A US expert panel consensus on measurable residual disease in adult acute lymphoblastic leukemia","volume":"9","author":"Short","year":"2024","journal-title":"Blood Adv."},{"issue":"17","key":"10.1016\/j.leukres.2026.108197_bib67","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.leukres.2026.108197_bib68","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib69","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108197_bib70","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2026.108197_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106283","article-title":"Impact of minimal residual disease status in patients with relapsed\/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial","volume":"88","author":"Jabbour","year":"2020","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2026.108197_bib72","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2026.108197_bib73","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108197_bib74","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2026.108197_bib75","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108197_bib76","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.leukres.2026.108197_bib77","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.leukres.2026.108197_bib78","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.leukres.2026.108197_bib79","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.leukres.2026.108197_bib80","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.leukres.2026.108197_bib81","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.2021013404","article-title":"Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status","volume":"139","author":"Roboz","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.leukres.2026.108197_bib82","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.leukres.2026.108197_bib83","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1182\/bloodadvances.2025016399","article-title":"Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML","volume":"9","author":"Montesinos","year":"2025","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib84","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2026.108197_bib85","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib86","first-page":"1028","article-title":"Revumenib, venetoclax, and decitabine in adults with relapsed\/refractory acute leukemia: preliminary results from the SAVE trial [abstract]","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib87","first-page":"620","article-title":"Ziftomenib in patients with acute myeloid leukemia with NPM1 mutation: results from the KOMET-007 trial [abstract]","volume":"144","author":"Erba","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib88","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41375-023-02072-y","article-title":"Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"38","author":"Bischof","year":"2024","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.leukres.2026.108197_bib89","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","article-title":"Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia","volume":"135","author":"Hasserjian","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108197_bib90","article-title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","author":"Cloos","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108197_bib91","first-page":"105","article-title":"Prognostic impact of the AML ELN2022 genetic risk classification in patients with NPM1 mutated AML","volume":"13","author":"Jentzsch","year":"2023","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.leukres.2026.108197_bib92","article-title":"Flow cytometry-based measurable residual disease monitoring in acute myeloid leukemia","volume":"36","author":"Tettero","year":"2023","journal-title":"Best. Pr. Res Clin. Haematol."},{"issue":"14","key":"10.1016\/j.leukres.2026.108197_bib93","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1182\/bloodadvances.2022009379","article-title":"Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study","volume":"7","author":"Scott","year":"2023","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.leukres.2026.108197_bib94","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s41375-024-02275-x","article-title":"Recommendations from the AML molecular MRD expert advisory board","volume":"38","author":"Scott","year":"2024","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2026.108197_bib95","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41375-024-02272-0","article-title":"Analysis of measurable residual disease by IG\/TR gene rearrangements: quality assurance and updated EuroMRD guidelines","volume":"38","author":"van der Velden","year":"2024","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.leukres.2026.108197_bib96","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108197_bib97","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ebiom.2018.10.042","article-title":"Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome","volume":"37","author":"Ko","year":"2018","journal-title":"EBioMedicine"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262600041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262600041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:07:08Z","timestamp":1774328828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262600041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":97,"alternative-id":["S014521262600041X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108197","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurable residual disease detection in acute leukemia: Technological advances and clinical translation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108197","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108197"}}